|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:second-generation_cephalosporin
gptkb:cephalosporin
|
|
gptkbp:ATCCode
|
J01DC02
|
|
gptkbp:bioavailability
|
37-52% (oral)
|
|
gptkbp:brand
|
Ceftin
Kefurox
Zinacef
|
|
gptkbp:CASNumber
|
55268-75-2
|
|
gptkbp:chemicalFormula
|
C16H16N4O8S
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:discoveredBy
|
Glaxo (now GSK)
|
|
gptkbp:drugClass
|
gptkb:antibiotic
|
|
gptkbp:eliminationHalfLife
|
1-1.5 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:introducedIn
|
1978
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:molecularWeight
|
424.39 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:prescribes
|
adults
children
|
|
gptkbp:proteinBinding
|
33-50%
|
|
gptkbp:resistantTo
|
some bacteria produce beta-lactamases that inactivate cefuroxime
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
rash
elevated liver enzymes
allergic reactions
eosinophilia
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:usedFor
|
gptkb:sinusitis
gptkb:otitis_media
skin infections
tonsillitis
urinary tract infections
gonorrhea
bacterial infections
respiratory tract infections
pharyngitis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cefuroxime
|